Chronic Lymphocytic Leukemia
Conditions
Keywords
CLL, obinutuzumab, treatment
Brief summary
This observational study aims to study the effectiveness and safety of Obinutuzumab in common clinical practice settings in Argentina. The study population comprises all patients with chronic lymphocytic leukemia (CLL) that have received the indication for treatment with Obinutuzumab as per routine clinical practice.
Interventions
BIOLOGICALObinutuzumab
Obinutuzumab will be administered as intravenous infusion for 6 cycles (28 days per cycle): 100 milligrams (mg) on day 1 Cycle 1, 900 mg on day 2 Cycle 1, 1000 mg on days 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6.
Sponsors
Hoffmann-La Roche
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have received at least one dose of Obinutuzumab as per local label and clinical practice.
Exclusion criteria
* Included in clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate | Up to 2 months after completion of 6 treatment cycles (up to approximately 8 months) | Overall response rate was defined as percentage of participants with complete response (CR) or partial response (PR). CR was defined as peripheral blood lymphocytes below 4 x 10\^9/liter (L), absence of significant lymphadenopathy, no hepatomegaly, no splenomegaly, absence of disease or B symptoms, neutrophils \>1.5 x 10\^9/L, platelets \>100 x 10\^9/L, hemoglobin \>11 grams/deciliter (g/dl) and bone marrow at least normocellular for age. PR was defined as \>=50% decrease in peripheral blood lymphocyte count, \>/=50% reduction in lymphadenopathy, \>/=50% reduction of liver enlargement and/or \>/=50% reduction of spleen enlargement, plus at least one of the following: neutrophils \>1.5 x 10\^9/L or \>/=50% increase, or platelets \>100 x 10\^9/L or ≥50% increase, or hemoglobin 11 g/dl or \>/=50% increase. Overall response rate = CR + PR |
| Percentage of Participants With Adverse Events (AEs) | Up to 24 months | An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response Rate | Up to 2 months after completion of 6 treatment cycles (up to approximately 8 months) | CR was defined as peripheral blood lymphocytes below 4 x 10\^9/liter (L), absence of significant lymphadenopathy, no hepatomegaly, no splenomegaly, absence of disease or B symptoms, neutrophils \>1.5 x 10\^9/L, platelets \>100 x 10\^9/L, hemoglobin 11 g/dl and bone marrow at least normocellular for age. |
| Partial Response Rate | Up to 2 months after completion of 6 treatment cycles (up to approximately 8 months) | PR was defined as \>=50% decrease in peripheral blood lymphocyte count from the pre-treatment value, \>/=50% reduction in lymphadenopathy, \>/=50% reduction of liver enlargement and/or \>/=50% reduction of spleen enlargement, plus at least one of the following: neutrophils \>1.5 x 10\^9/L or \>/=50% increase, or platelets \>100 x 10\^9/L or ≥50% increase, or hemoglobin 11 g/dl or \>/=50% increase. |
| Progression-free Survival (PFS) | After the completion of treatment, at 12 and 24 months after start of treatment | PFS is defined as the time from the first dose of treatment to the first occurrence of progression, or death from any cause as assessed by the physician. Progressive disease is defined by any of the following: \>/=50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, \>/=50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, \>/=50% increase in the enlargement of the liver and/or spleen, transformation to a more aggressive histology, after treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>2 g/dL or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10x9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L), excluding immune causes. |
| Median Duration of Response | Up to 24 months | Duration of response is defined as the time from the date the response (either CR or PR) was first recorded until the date of disease progression or death due to any cause. Disease progression is defined by any of the following: \>/=50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, \>/=50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, \>/=50% increase in the enlargement of the liver and/or spleen, transformation to a more aggressive histology, after treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>2 g/dL or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10x9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L), excluding immune causes. |
Countries
Argentina
Outcome results
None listed